(Q34575937)

3 August 2017

1 reference

title

Are high-density lipoprotein and triglyceride levels important in secondary prevention: impressions from the BIP and VA-HIT trials (English)

1 reference

3 August 2017

1 reference

1 reference

Rizos E

1

1 reference

3 August 2017

Mikhailidis DP

series ordinal

2

1 reference

3 August 2017

publication date

1 March 2002

1 reference

International Journal of Cardiology

3 August 2017

published in

1 reference

3 August 2017

volume

82

1 reference

3 August 2017

issue

3

1 reference

3 August 2017

page(s)

199-207; discussion 207-8

1 reference

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900625-8

7 January 2021

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900625-8

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900625-8

7 January 2021

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900625-8

7 January 2021

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900625-8

7 January 2021

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900625-8

7 January 2021

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900625-8

7 January 2021

The new pathophysiology of coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900625-8

7 January 2021

Raising low levels of high-density lipoprotein cholesterol is an important target of therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900625-8

7 January 2021

Evidence that triglycerides are an independent coronary heart disease risk factor

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900625-8

7 January 2021

Elevated serum triglyceride levels and long-term mortality in patients with coronary heart disease: the Bezafibrate Infarction Prevention (BIP) Registry

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900625-8

7 January 2021

Pathophysiology and management of low high-density lipoprotein cholesterol

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900625-8

7 January 2021

Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900625-8

7 January 2021

High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900625-8

7 January 2021

Conclusions from the VA-HIT study

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900625-8

7 January 2021

Are drugs within a class interchangeable?

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900625-8

7 January 2021

The HDL receptor SR-BI: a new therapeutic target for atherosclerosis?

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900625-8

7 January 2021

Overexpression of the HDL receptor SR-BI alters plasma HDL and bile cholesterol levels

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900625-8

7 January 2021

Fibrates and statins in the treatment of hyperlipidaemia: an appraisal of their efficacy and safety

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900625-8

7 January 2021

Treating dyslipidaemia in non-insulin-dependent diabetes mellitus -- a special reference to statins

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900625-8

7 January 2021

Smoking diminishes the beneficial effect of statins: observations from the landmark trials

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900625-8

7 January 2021

Lipids and stroke: neglect of a useful preventive measure?

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900625-8

7 January 2021

Are high density lipoprotein (HDL) and triglyceride levels relevant in stroke prevention?

1 reference

https://api.crossref.org/works/10.1016%2FS0167-5273%2801%2900625-8

7 January 2021

10.1016/S0167-5273(01)00625-8

Identifiers

DOI

1 reference

3 August 2017

1 reference